In addition, redox regulated signaling has provided new strategies to enhance cancer therapy that have included modification of signal transduction, immune signaling, inhibition of nitric oxide synthase 2 (NOS2), and cyclooxygenase 2 (COX2), which have all shown promise in preclinical and even clinical trials [4,5,6]. The gene discussed is PTGS2; the disease is cancer.